“Afrigen Biologics has earned Good Manufacturing Practice (GMP) certification from the South African Health Products Regulatory Authority (SAHPRA), validating Africa’s first fully integrated mRNA manufacturing facility. This milestone strengthens Africa’s ability to produce investigational biological products for clinical trials, reduces reliance on imported vaccines, and enhances pandemic preparedness.”
South Africa’s biotechnology sector has entered a defining era with Afrigen Biologics achieving GMP certification for its Cape Town-based mRNA manufacturing facility. This achievement is not only a national triumph but also a continental breakthrough, symbolizing Africa’s growing capacity to produce advanced vaccines and biologics.
Why GMP Certification Matters
- Global Standards Compliance: GMP certification ensures adherence to internationally recognized safety and quality benchmarks.
- Clinical Trial Readiness: Afrigen can now manufacture investigational biological products for Phase I and II clinical trials.
- Health Sovereignty: By reducing reliance on imports, South Africa strengthens its ability to respond to pandemics and supply vaccines locally.
Lessons from COVID-19
The COVID-19 pandemic exposed Africa’s vulnerability in vaccine access. Wealthy nations secured doses early, while African countries faced delays and shortages. Afrigen’s facility directly addresses this inequity, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset.
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Voices of Leadership
Prof. Petro Terblanche, CEO of Afrigen, emphasized: “This certification is a tribute to the extraordinary commitment of our team. We are ready to support clinical trial production and contribute meaningfully to vaccine development.”
Broader Implications
- Economic Growth: The facility is expected to attract investment, create jobs, and stimulate South Africa’s biotech industry.
- Scientific Advancement: Local scientists gain access to cutting-edge technology, fostering innovation.
- Continental Collaboration: Afrigen’s hub will serve as a model for other African nations seeking biotech independence.
Challenges Ahead
- Scaling Production: Moving from pilot-scale to mass production will require significant investment.
- Regulatory Hurdles: Maintaining compliance with evolving international standards is critical.
- Global Competition: Afrigen must compete with established pharmaceutical giants while carving out its niche in Africa.
Conclusion
Afrigen’s GMP certification represents a turning point for Africa’s biotechnology landscape. It signals readiness not only to participate in global vaccine innovation but also to lead in ensuring equitable access across the continent. South Africa has positioned itself as a beacon of biotech sovereignty, resilience, and innovation.
